Oncosil Medical (OSL) Company Update Oncosil Medical (OSL) | OVERWEIGHT: Upgrade anticipating European approvalLife Sciences Tools and Services TP $0.30 OVERWEIGHT Shane Storey +61 7 3212 1351 | Elyse Shapiro +61 3 9640 3864 We move further OVERWEIGHT Oncosil anticipating imminent European approval for OncoSilTM. The company continued to work with regulators over the break to finalise its post-approval plans. If successful, the product will become commercially available in Europe for the treatment of pancreatic cancer. Separately, Oncosil’s pursuit of a humanitarian approval in the USA remains on track as another source of potential income this year. These unexpected but welcome reversals of fortune mean that Oncosil’s valuation is reconnecting with fundamentals. Our new price target is $0.30 per share (+62%). Catalysts over the next 3-4 months could support valuation gains up to $1.20 per share (un-risked asset value, fully diluted basis).
OSL Price at posting:
17.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)